Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Worth remembering that following the AACR conference in the US, we have the ESMO oncology conference in Madrid on the 20-24/10, with all the majors attending.
Excellent timing for Avacta having presented at the ACCR conference.
One of the majors presenting on Precision Oncology:
Friday:
Bayer - Delivering on the Promise of Precision Oncology: From the Big Bang to Tangible Impact on Patients’ Lives.
As mentioned before, this year’s ESMO conference will be dominated by precision oncology and M&A .
Following Eli Lilly’s acquisition of Point Biopharma and Avacta’s exposure to that transaction, worth reminding ourselves that we ESMO 2023 later this month, October 20-24/10,The ESMO Congress is a highly influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.
ESMO 2023 will work towards the dissemination of the latest data, provide high quality education and excellent networking opportunities for oncologists and other stakeholders from all around the world.
Bayer presenting on Precision Oncology on 20/10. The conference will only highlight the investment case for Avacta.
JT, I agree with some of your views, however I personally believe there is already a license deal in place with a major, hence the CEO’s answer to the question regarding working capital” would not worry about that “, hence the of group of majors who would be interested, have no doubt worked out, which of the large cap Pharma’s won the bidding war and we will no doubt have that RNS very soon. This will of course accelerate the process of a Therapeutic IPO state side and also change the structure of the shareholder list significantly in favour of a 90/10 % institutional vs retail.
To be able to pick up stock at current levels is very much Christmas arrived early.
Size buyers will step up the pace, before it is too late.
We have AVA6000 and 3996, but as the CEO mentioned, it is also about the AVA platform !!
The majors will be knocking on the door and now with Dr. Tap and the FDA working with us, it is only a matter of time before the conference in Boston.
Size buyers will have a busy 1st week in October ahead of them.
Increase of their equity holding in Affyxell :
“This will result in an increase in Avacta's shareholding in AffyXell to approximately 25% from its current 19%, which will be determined when a formal valuation has been completed as was done for the first milestone payment.”
The 6% increase in their ownership of Affyxell, will look even more interesting for Avacta , once the IPO of the Korean company gets underway!
A great question for the company during Q&A, what value does Avacta apply to their zero cost holding?
Interesting comments, keep them coming.
PS
do you have the canoccord note?
Thanks